Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion issued a clarification disclosure stating that it signed a KRW 300.0B Memorandum of Agreement (MOA) with South Chungcheong Province, Yesan-gun, and Chungnam Development Corporation for the construction of a drug product (DP) facility in Yesan, with a re-disclosure planned upon confirmation or within 6 months (by August 27, 2025).
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Clarification of Rumors or News Reports (Unconfirmed)
- Subject Rumor / News Report: Reports regarding “Celltrion to build Chungnam plant: 300 billion won investment by 2028” (Seoul Economic Daily, 2023-12-01)
- Details of Clarification & Progress of Agreement
- Nov 30, 2023: Signed a Memorandum of Understanding (MOU) with Yesan-gun, South Chungcheong Province, for a KRW 300.0B investment in a biopharmaceutical and related materials facility through December 2028.
- Feb 27, 2025: Signed a Memorandum of Agreement (MOA) with South Chungcheong Province, Yesan-gun, and Chungnam Development Corporation for the construction of a KRW 300.0B drug product (DP) facility.
- Specific terms including investment period and amount are subject to change based on further consultations.
- Re-disclosure Schedule
- Re-disclosure will be made when detailed terms are finalized or within 6 months.
- Scheduled Re-disclosure Date: 2025-08-27
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Final Confirmation and Re-disclosure regarding Yesan DP Facility Construction
This disclosure serves as an unconfirmed clarification regarding progress following the MOA execution for the Yesan plant construction. Reviewing whether detailed execution plans regarding investment timelines and amounts are finalized in subsequent disclosures or addressed by the scheduled re-disclosure date (August 27, 2025) is important for assessing the realization of the facility investment. Relevant updates can be confirmed through subsequent re-disclosures or official company announcements.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
